Google_______________

Liver Stiffness Measurement Helps Clinicians Assess Liver Fibrosis

By Liz Highleyman

Liver biopsy is considered the "gold standard" for assessing liver disease progression, but given that the procedure is uncomfortable and expensive, researchers have sought to develop non-invasive methods for measuring liver fibrosis. One such measure is liver stiffness, assessed using a technique known as transient elastography (FibroScan).

As reported in the December 2006 American Journal of Gastroenterology, French researchers estimated the additional value of liver stiffness measurement (LSM) when used in conjunction with epidemiological, clinical, and biological parameters.

The study included 142 unselected patients with chronic hepatitis C. Liver biopsy and LSM were performed simultaneously. First, 4 physicians -- 2 junior residents with limited experience in hepatology and 2 senior hepatologists -- independently predicted the patients' liver fibrosis stage (METAVIR classification) using clinical, epidemiological, and biological data. Then, the physicians were informed of patients' LSM values and allowed to modify their initial evaluation. Finally, the 2 successive evaluations were compared with the histological fibrosis score as determined by biopsy.

Results

Providing LSM values improved agreement among physicians and resulted in a better correlation between clinical impression and histological fibrosis scores.

Diagnostic performance was only significantly improved with transient elastography for the diagnosis of cirrhosis, where assessment improved in 3 of the 4 physicians.

Performance was similar for junior and senior physicians when LSM was provided.

Areas under the receiver operating curve (AUROC) ranged from 0.69 to 0.72 for significant fibrosis, and from 0.87 to 0.90 for cirrhosis.

Conclusion

"Providing LSM values to physicians results in a better estimation of liver fibrosis and a more accurate diagnosis of cirrhosis," the authors concluded. "Moreover, it allows physicians with limited experience to predict liver fibrosis as well as experienced hepatologists."

The results of this study support the usefulness of transient elastography under certain circumstances, but are in accord with past research showing that the technique works best for diagnosing advanced fibrosis or cirrhosis, but performs less well at detecting mild-to-moderate liver disease.

02/02/07

Reference
P Nahon, G Thabut, M Ziol, and others. Liver stiffness measurement versus clinicians' prediction or both for the assessment of liver fibrosis in patients with chronic hepatitis C. American Journal of Gastroenterology 101(12): 2744-2751. December 2006.


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Index of All
Hepatitis C Articles
by Topic ( A to Z)